Harvard Bioscience (HBIO) & Cytosorbents (CTSO) Head-To-Head Review

Harvard Bioscience (NASDAQ: HBIO) and Cytosorbents (NASDAQ:CTSO) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.


This table compares Harvard Bioscience and Cytosorbents’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Harvard Bioscience -0.85% 2.38% 1.64%
Cytosorbents -52.08% -118.07% -40.15%

Analyst Ratings

This is a breakdown of current ratings and target prices for Harvard Bioscience and Cytosorbents, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harvard Bioscience 0 0 2 0 3.00
Cytosorbents 0 0 5 0 3.00

Harvard Bioscience currently has a consensus price target of $9.00, suggesting a potential upside of 89.47%. Cytosorbents has a consensus price target of $11.05, suggesting a potential upside of 36.42%. Given Harvard Bioscience’s higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Cytosorbents.

Valuation & Earnings

This table compares Harvard Bioscience and Cytosorbents’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Harvard Bioscience $101.88 million 1.63 -$870,000.00 ($0.02) -237.50
Cytosorbents $15.15 million 15.76 -$8.46 million ($0.28) -28.93

Harvard Bioscience has higher revenue and earnings than Cytosorbents. Harvard Bioscience is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Harvard Bioscience has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500.

Insider & Institutional Ownership

63.5% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 11.1% of Cytosorbents shares are owned by institutional investors. 9.8% of Harvard Bioscience shares are owned by insiders. Comparatively, 5.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Harvard Bioscience beats Cytosorbents on 10 of the 12 factors compared between the two stocks.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.

Cytosorbents Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply